Spaces:
Running
Running
File size: 131,886 Bytes
9754890 |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1690 1691 1692 1693 1694 1695 1696 1697 1698 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 1811 1812 1813 1814 1815 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 |
{
"cells": [
{
"cell_type": "code",
"execution_count": 9,
"metadata": {},
"outputs": [],
"source": [
"from selenium import webdriver\n",
"from selenium.webdriver.common.by import By\n",
"from selenium.webdriver.support.ui import WebDriverWait\n",
"from selenium.webdriver.support import expected_conditions as EC\n",
"import csv\n",
"\n",
"\n",
"from selenium import webdriver\n",
"from selenium.webdriver.common.by import By\n",
"from selenium.webdriver.support.ui import WebDriverWait\n",
"from selenium.webdriver.support import expected_conditions as EC\n",
"import csv\n",
"\n",
"# CSVファイルの保存設定\n",
"output_file = \"search_results.csv\"\n",
"\n",
"# WebDriverを初期化\n",
"driver = webdriver.Chrome() # 必要に応じてChromeDriverを設定\n"
]
},
{
"cell_type": "code",
"execution_count": 10,
"metadata": {},
"outputs": [],
"source": [
"def fetch_clinical_trials(disease_name=\"\", freeword=\"\"):\n",
" \"\"\"\n",
" 指定された対象疾患名およびフリーワード検索に基づいてjRCTから臨床試験情報を取得します。\n",
"\n",
" Args:\n",
" disease_name (str): 対象疾患名（例: \"がん 神経膠腫 骨髄腫\"）\n",
" freeword (str): フリーワード検索（例: \"免疫療法\"）\n",
"\n",
" Returns:\n",
" list: 検索結果のリスト（[試験ID, タイトル, 対象疾患, 進捗状況, 日付, リンク]）\n",
" \"\"\"\n",
" # WebDriverを初期化\n",
" driver = webdriver.Chrome() # 必要に応じてChromeDriverを設定\n",
"\n",
" all_results = []\n",
"\n",
" try:\n",
" # jRCTの検索ページにアクセス\n",
" driver.get(\"https://jrct.niph.go.jp/search\")\n",
"\n",
" # 対象疾患名を入力\n",
" if disease_name:\n",
" disease_field = WebDriverWait(driver, 10).until(\n",
" EC.presence_of_element_located((By.ID, \"reg-plobrem-1\"))\n",
" )\n",
" disease_field.send_keys(disease_name)\n",
"\n",
" # 対象疾患名の条件を「or」に設定\n",
" condition_select = driver.find_element(By.ID, \"reg-plobrem-type\")\n",
" condition_select.find_element(By.CSS_SELECTOR, \"option[value='1']\").click()\n",
"\n",
" # フリーワード検索を入力\n",
" if freeword:\n",
" freeword_field = WebDriverWait(driver, 10).until(\n",
" EC.presence_of_element_located((By.ID, \"demo-1\"))\n",
" )\n",
" freeword_field.send_keys(freeword)\n",
"\n",
" # フリーワード検索の条件を「or」に設定\n",
" condition_select = driver.find_element(By.ID, \"others\")\n",
" condition_select.find_element(By.CSS_SELECTOR, \"option[value='1']\").click()\n",
"\n",
" # 募集中を選択\n",
" recruitment_checkbox = driver.find_element(By.ID, \"reg-recruitment-2\")\n",
" recruitment_checkbox.click()\n",
"\n",
" # 検索ボタンをクリック\n",
" search_button = driver.find_element(By.NAME, \"button_type\")\n",
" search_button.click()\n",
"\n",
" # ページネーション対応ループ\n",
" while True:\n",
" # 現在のページの結果がロードされるのを待機\n",
" WebDriverWait(driver, 10).until(\n",
" EC.presence_of_element_located((By.CSS_SELECTOR, \"table tbody tr\"))\n",
" )\n",
"\n",
" # 現在のページの結果を取得\n",
" rows = driver.find_elements(By.CSS_SELECTOR, \"table tbody tr\")\n",
" for row in rows:\n",
" columns = row.find_elements(By.TAG_NAME, \"td\")\n",
" if len(columns) > 4:\n",
" # 試験情報をリストに追加\n",
" trial_id = columns[0].text\n",
" title = columns[1].text\n",
" condition = columns[2].text\n",
" status = columns[3].text\n",
" date = columns[4].text\n",
"\n",
" # リンクを取得（エラー処理を追加）\n",
" try:\n",
" link = columns[1].find_element(By.TAG_NAME, \"a\").get_attribute(\"href\")\n",
" except Exception as e:\n",
" link = \"リンク取得エラー\"\n",
"\n",
" all_results.append([trial_id, title, condition, status, date, link])\n",
"\n",
" # ページネーションの確認\n",
" try:\n",
" current_page = driver.find_element(By.CSS_SELECTOR, \"ul.pagination li.active\").text\n",
" print(f\"{current_page} ページ目を処理しました。\")\n",
" except Exception:\n",
" print(\"ページネーションが存在しません。全ての結果を取得しました。\")\n",
" break\n",
"\n",
" # 次ページボタンのリストを取得\n",
" pagination_buttons = driver.find_elements(By.CSS_SELECTOR, \"ul.pagination li a\")\n",
" next_button = None\n",
" for button in pagination_buttons:\n",
" if button.text.isdigit() and int(button.text) > int(current_page):\n",
" next_button = button\n",
" break\n",
"\n",
" if next_button:\n",
" next_button.click()\n",
" WebDriverWait(driver, 10).until(EC.staleness_of(rows[0])) # ページが変わるまで待機\n",
" else:\n",
" print(\"次のページはありません。全ての結果を取得しました。\")\n",
" break\n",
"\n",
" finally:\n",
" # ブラウザを閉じる\n",
" driver.quit()\n",
"\n",
" return all_results\n"
]
},
{
"cell_type": "markdown",
"metadata": {},
"source": [
"def create_dataframe_from_urls(urls):\n",
" \"\"\"\n",
" URLのリストを受け取り、pandas DataFrameを作成します。\n",
" \"\"\"\n",
" \n",
" all_data = []\n",
"\n",
" for url in urls:\n",
" print(f\"Processing URL: {url}\")\n",
" # 各メソッドを使ってデータを取得\n",
" purpose = scrape_study_purpose(url)\n",
" design_details = scrape_jrct_details_with_english(url)\n",
" additional_details = scrape_jrct_details(url)\n",
"\n",
" # 統合する\n",
" data = {\"研究・治験の目的\": purpose, **design_details, **additional_details}\n",
" all_data.append(data)\n",
"\n",
" # pandas DataFrameに変換\n",
" return pd.DataFrame(all_data)"
]
},
{
"cell_type": "markdown",
"metadata": {},
"source": []
},
{
"cell_type": "code",
"execution_count": 11,
"metadata": {},
"outputs": [],
"source": [
"import pandas as pd\n",
"import requests\n",
"from bs4 import BeautifulSoup\n",
"\n",
"def scrape_study_purpose(url):\n",
" \"\"\"\n",
" 指定されたjRCT URLから研究・治験の目的を抽出します。\n",
" \"\"\"\n",
" response = requests.get(url)\n",
" response.raise_for_status()\n",
" soup = BeautifulSoup(response.text, 'html.parser')\n",
"\n",
" # \"研究・治験の目的\" を特定\n",
" purpose_label = soup.find('label', text='研究・治験の目的')\n",
" if purpose_label:\n",
" # \"研究・治験の目的\" に対応するデータを取得\n",
" purpose_td = purpose_label.find_parent('th').find_next_sibling('td')\n",
" if purpose_td:\n",
" return purpose_td.text.strip()\n",
"\n",
" return None\n",
"\n",
"\n",
"def scrape_jrct_details_with_english(url):\n",
" \"\"\"\n",
" 指定されたjRCT URLから試験デザイン情報（日本語と英語の両方）を抽出します。\n",
" \"\"\"\n",
" response = requests.get(url)\n",
" response.raise_for_status()\n",
" soup = BeautifulSoup(response.text, 'html.parser')\n",
"\n",
" data = {\"URL\": url}\n",
"\n",
" # 試験デザイン項目（日本語と英語をペアで取得）\n",
" design_labels = [\n",
" ('試験の種類', 'Study Type'),\n",
" ('無作為化', 'allocation'),\n",
" ('盲検化', 'masking'),\n",
" ('対照', 'control'),\n",
" ('割付け', 'assignment'),\n",
" ('研究目的', 'purpose')\n",
" ]\n",
"\n",
" for label_jp, label_en in design_labels:\n",
" label = soup.find('label', string=lambda text: text and label_jp in text)\n",
" if label:\n",
" # 日本語部分のtd\n",
" td_jp = label.find_parent('th').find_next_sibling('td')\n",
" # 英語部分のtd（次のtd要素）\n",
" td_en = td_jp.find_next_sibling('td') if td_jp else None\n",
"\n",
" # データに日本語と英語を追加\n",
" data[label_jp] = td_jp.text.strip() if td_jp else None\n",
" data[label_en] = td_en.text.strip() if td_en else None\n",
"\n",
" return data\n",
"\n",
"\n",
"def scrape_jrct_details(url):\n",
" \"\"\"\n",
" jRCTの指定URLから、必要な情報を抽出します。\n",
" \"\"\"\n",
" response = requests.get(url)\n",
" response.raise_for_status()\n",
" soup = BeautifulSoup(response.text, 'html.parser')\n",
"\n",
" data = {\"URL\": url}\n",
"\n",
" # 抽出項目とラベルの対応\n",
" labels = [\n",
" ('主たる選択基準', 'Inclusion Criteria'),\n",
" ('主たる除外基準', 'Exclusion Criteria'),\n",
" ('年齢下限', 'Age Minimum'),\n",
" ('年齢上限', 'Age Maximum'),\n",
" ('性別', 'Gender'),\n",
" ('中止基準', 'Discontinuation Criteria'),\n",
" ('対象疾患キーワード', 'Keyword'),\n",
" ('介入の内容', 'Intervention(s)')\n",
" ]\n",
"\n",
" for label_jp, label_en in labels:\n",
" # 日本語ラベルを検索\n",
" label = soup.find('label', string=lambda text: text and label_jp in text)\n",
" if label:\n",
" # 日本語部分のデータ\n",
" td_jp = label.find_parent('th').find_next_sibling('td')\n",
" # 英語部分のデータ\n",
" td_en = td_jp.find_next_sibling('td') if td_jp else None\n",
"\n",
" # データに追加\n",
" data[label_jp] = td_jp.decode_contents().strip().replace('<br/>', '\\n') if td_jp else None\n",
" data[label_en] = td_en.decode_contents().strip().replace('<br/>', '\\n') if td_en else None\n",
"\n",
" return data\n",
"\n",
"\n",
"def extract_jrct_links(results):\n",
" \"\"\"\n",
" fetch_clinical_trialsの結果からjRCT-Noを抽出し、詳細リンクを作成する。\n",
"\n",
" Args:\n",
" results (list): fetch_clinical_trialsから得られる結果リスト\n",
"\n",
" Returns:\n",
" list: jRCTの詳細ページリンクリスト\n",
" \"\"\"\n",
" base_url = \"https://jrct.niph.go.jp/latest-detail/\"\n",
" links = []\n",
" for result in results:\n",
" if len(result) > 0:\n",
" jrct_no = result[0] # jRCT-Noは結果リストの最初の要素\n",
" links.append(base_url + jrct_no)\n",
" return links\n",
"\n",
"\n",
"def create_dataframe_from_urls(urls):\n",
" \"\"\"\n",
" URLのリストを受け取り、pandas DataFrameを作成します。\n",
" \"\"\"\n",
" all_data = []\n",
"\n",
" for url in urls:\n",
" print(f\"Processing URL: {url}\")\n",
" # 各メソッドを使ってデータを取得\n",
" purpose = scrape_study_purpose(url)\n",
" design_details = scrape_jrct_details_with_english(url)\n",
" additional_details = scrape_jrct_details(url)\n",
"\n",
" # 統合する\n",
" data = {\"研究・治験の目的\": purpose, **design_details, **additional_details}\n",
" all_data.append(data)\n",
"\n",
" # pandas DataFrameに変換\n",
" return pd.DataFrame(all_data)\n",
"\n",
"def reorder_columns(df):\n",
" \"\"\"\n",
" DataFrame の列を日本語の列を前半に、英語の列を後半に並び替える。\n",
" \"\"\"\n",
" # 日本語と英語の列を分ける\n",
" jp_columns = [col for col in df.columns if all(ord(c) < 128 for c in col) is False] # 非 ASCII（日本語）文字列を含む列\n",
" en_columns = [col for col in df.columns if col not in jp_columns] # 残りの列を英語と仮定\n",
"\n",
" # 日本語列 + 英語列の順序で整列\n",
" ordered_columns = jp_columns + en_columns\n",
"\n",
" # 列を並び替えた DataFrame を返す\n",
" return df[ordered_columns]"
]
},
{
"cell_type": "code",
"execution_count": 12,
"metadata": {},
"outputs": [
{
"name": "stdout",
"output_type": "stream",
"text": [
"ページネーションが存在しません。全ての結果を取得しました。\n"
]
}
],
"source": [
"# WebDriverを初期化\n",
"driver = webdriver.Chrome() # 必要に応じてChromeDriverを設定\n",
"\n",
"# fetch_clinical_trialsを使って検索結果を取得\n",
"results = fetch_clinical_trials(disease_name=\"神経膠腫 骨髄腫\", freeword=\"\")"
]
},
{
"cell_type": "code",
"execution_count": 13,
"metadata": {},
"outputs": [
{
"name": "stdout",
"output_type": "stream",
"text": [
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051240141\n"
]
},
{
"name": "stderr",
"output_type": "stream",
"text": [
"/var/folders/yw/qz00x75d7kb98f7vm8dkhkvw0000gn/T/ipykernel_40777/81950631.py:14: DeprecationWarning: The 'text' argument to find()-type methods is deprecated. Use 'string' instead.\n",
" purpose_label = soup.find('label', text='研究・治験の目的')\n"
]
},
{
"name": "stdout",
"output_type": "stream",
"text": [
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051240121\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT1031240239\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2041240056\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021240013\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031240090\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031240014\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2041240003\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230660\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021230055\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2061230084\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2071230097\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2071230095\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2011230049\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051230108\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051230069\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230223\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051230065\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230087\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2032230060\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT1070230005\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230009\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230007\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2041220125\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021220036\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2063220071\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021220022\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2033220220\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031220060\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs051220019\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2053220006\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031210635\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031210607\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2033210469\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs071210084\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs071210074\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031210299\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2011210025\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051210043\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs031200320\n"
]
},
{
"ename": "HTTPError",
"evalue": "403 Client Error: Forbidden for url: https://jrct.niph.go.jp/latest-detail/jRCTs031200320",
"output_type": "error",
"traceback": [
"\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
"\u001b[0;31mHTTPError\u001b[0m Traceback (most recent call last)",
"Cell \u001b[0;32mIn[13], line 5\u001b[0m\n\u001b[1;32m 2\u001b[0m jrct_links \u001b[38;5;241m=\u001b[39m extract_jrct_links(results)\n\u001b[1;32m 4\u001b[0m \u001b[38;5;66;03m# 詳細リンクからデータフレームを作成\u001b[39;00m\n\u001b[0;32m----> 5\u001b[0m df \u001b[38;5;241m=\u001b[39m \u001b[43mcreate_dataframe_from_urls\u001b[49m\u001b[43m(\u001b[49m\u001b[43mjrct_links\u001b[49m\u001b[43m)\u001b[49m\n",
"Cell \u001b[0;32mIn[11], line 125\u001b[0m, in \u001b[0;36mcreate_dataframe_from_urls\u001b[0;34m(urls)\u001b[0m\n\u001b[1;32m 123\u001b[0m \u001b[38;5;28mprint\u001b[39m(\u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mProcessing URL: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00murl\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m 124\u001b[0m \u001b[38;5;66;03m# 各メソッドを使ってデータを取得\u001b[39;00m\n\u001b[0;32m--> 125\u001b[0m purpose \u001b[38;5;241m=\u001b[39m \u001b[43mscrape_study_purpose\u001b[49m\u001b[43m(\u001b[49m\u001b[43murl\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m 126\u001b[0m design_details \u001b[38;5;241m=\u001b[39m scrape_jrct_details_with_english(url)\n\u001b[1;32m 127\u001b[0m additional_details \u001b[38;5;241m=\u001b[39m scrape_jrct_details(url)\n",
"Cell \u001b[0;32mIn[11], line 10\u001b[0m, in \u001b[0;36mscrape_study_purpose\u001b[0;34m(url)\u001b[0m\n\u001b[1;32m 6\u001b[0m \u001b[38;5;250m\u001b[39m\u001b[38;5;124;03m\"\"\"\u001b[39;00m\n\u001b[1;32m 7\u001b[0m \u001b[38;5;124;03m指定されたjRCT URLから研究・治験の目的を抽出します。\u001b[39;00m\n\u001b[1;32m 8\u001b[0m \u001b[38;5;124;03m\"\"\"\u001b[39;00m\n\u001b[1;32m 9\u001b[0m response \u001b[38;5;241m=\u001b[39m requests\u001b[38;5;241m.\u001b[39mget(url)\n\u001b[0;32m---> 10\u001b[0m \u001b[43mresponse\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mraise_for_status\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m 11\u001b[0m soup \u001b[38;5;241m=\u001b[39m BeautifulSoup(response\u001b[38;5;241m.\u001b[39mtext, \u001b[38;5;124m'\u001b[39m\u001b[38;5;124mhtml.parser\u001b[39m\u001b[38;5;124m'\u001b[39m)\n\u001b[1;32m 13\u001b[0m \u001b[38;5;66;03m# \"研究・治験の目的\" を特定\u001b[39;00m\n",
"File \u001b[0;32m~/miniforge3/envs/gradio/lib/python3.12/site-packages/requests/models.py:1024\u001b[0m, in \u001b[0;36mResponse.raise_for_status\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m 1019\u001b[0m http_error_msg \u001b[38;5;241m=\u001b[39m (\n\u001b[1;32m 1020\u001b[0m \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mstatus_code\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m Server Error: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mreason\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m for url: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39murl\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m 1021\u001b[0m )\n\u001b[1;32m 1023\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m http_error_msg:\n\u001b[0;32m-> 1024\u001b[0m \u001b[38;5;28;01mraise\u001b[39;00m HTTPError(http_error_msg, response\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mself\u001b[39m)\n",
"\u001b[0;31mHTTPError\u001b[0m: 403 Client Error: Forbidden for url: https://jrct.niph.go.jp/latest-detail/jRCTs031200320"
]
}
],
"source": [
" # jRCT詳細リンクを作成\n",
"jrct_links = extract_jrct_links(results)\n",
"\n",
" # 詳細リンクからデータフレームを作成\n",
"df = create_dataframe_from_urls(jrct_links)"
]
},
{
"cell_type": "code",
"execution_count": 20,
"metadata": {},
"outputs": [],
"source": [
"# 整列後の DataFrame を作成\n",
"sorted_df = reorder_columns(df)"
]
},
{
"cell_type": "code",
"execution_count": 25,
"metadata": {},
"outputs": [
{
"name": "stderr",
"output_type": "stream",
"text": [
"/var/folders/yw/qz00x75d7kb98f7vm8dkhkvw0000gn/T/ipykernel_36648/2325933109.py:1: SettingWithCopyWarning: \n",
"A value is trying to be set on a copy of a slice from a DataFrame.\n",
"Try using .loc[row_indexer,col_indexer] = value instead\n",
"\n",
"See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
" sorted_df['JRCT ID'] = [result[0] for result in results]\n",
"/var/folders/yw/qz00x75d7kb98f7vm8dkhkvw0000gn/T/ipykernel_36648/2325933109.py:2: SettingWithCopyWarning: \n",
"A value is trying to be set on a copy of a slice from a DataFrame.\n",
"Try using .loc[row_indexer,col_indexer] = value instead\n",
"\n",
"See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
" sorted_df['Title'] = [result[1] for result in results]\n"
]
}
],
"source": [
"sorted_df['JRCT ID'] = [result[0] for result in results]\n",
"sorted_df['Title'] = [result[1] for result in results]"
]
},
{
"cell_type": "code",
"execution_count": 27,
"metadata": {},
"outputs": [],
"source": [
"new_order = [\"JRCT ID\", \"Title\"] + [col for col in sorted_df.columns if col not in [\"JRCT ID\", \"Title\"]]"
]
},
{
"cell_type": "code",
"execution_count": 28,
"metadata": {},
"outputs": [],
"source": [
"sorted_df = sorted_df[new_order]"
]
},
{
"cell_type": "code",
"execution_count": 29,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>JRCT ID</th>\n",
" <th>Title</th>\n",
" <th>研究・治験の目的</th>\n",
" <th>URL</th>\n",
" <th>無作為化</th>\n",
" <th>allocation</th>\n",
" <th>盲検化</th>\n",
" <th>masking</th>\n",
" <th>対照</th>\n",
" <th>control</th>\n",
" <th>...</th>\n",
" <th>性別</th>\n",
" <th>Gender</th>\n",
" <th>中止基準</th>\n",
" <th>Discontinuation Criteria</th>\n",
" <th>対象疾患キーワード</th>\n",
" <th>Keyword</th>\n",
" <th>介入の内容</th>\n",
" <th>Intervention(s)</th>\n",
" <th>試験の種類</th>\n",
" <th>Study Type</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>0</th>\n",
" <td>jRCT2051240141</td>\n",
" <td>新たに診断され放射線療法を完了したH3 K27M変異を有するびまん性神経膠腫の治療のためのO...</td>\n",
" <td>H3 K27M変異びまん性神経膠腫を有する被験者を対象に、放射線療法後に投与されたONC20...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2051...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>二重盲検</td>\n",
" <td>double blind</td>\n",
" <td>プラセボ対照</td>\n",
" <td>placebo control</td>\n",
" <td>...</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>被験者は、ベースラインでONC201週2回投与群、ONC201週1回投与群又はプラセボ投与群...</td>\n",
" <td>Participants will be randomized at baseline in...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>1</th>\n",
" <td>jRCT2051240121</td>\n",
" <td>放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...</td>\n",
" <td>放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2051...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>active control</td>\n",
" <td>...</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>薬物 アベマシクリブ\\n\\r\\n経口投与\\n\\r\\nその他の名称 LY2835219\\n\\r...</td>\n",
" <td>Drug: Abemaciclib\\n\\r\\nAdministered orally\\n\\r...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>2</th>\n",
" <td>jRCT1031240239</td>\n",
" <td>JCOG2303: 可及的摘出されたIDH変異型星細胞腫の術後化学放射線療法に対する待機化学...</td>\n",
" <td>手術で可及的摘出（90%以上の摘出）されたIDH変異型星細胞腫Grade 3を対象に、標準治...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT1031...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>active control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td>＜患者の中止について＞\\n\\r\\n(1) プロトコール治療無効と判断\\n\\r\\n(2) 有害...</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>A群：標準治療群[術後化学放射線療法]/ B群：試験治療群[Watch &amp; Wait...</td>\n",
" <td>Group A: Standard treatment group [Adjuvant ch...</td>\n",
" <td>介入研究</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" <tr>\n",
" <th>3</th>\n",
" <td>jRCT2041240056</td>\n",
" <td>[M23-001] 再発性又は難治性多発性骨髄腫患者を対象にABBV-383 を皮下投与する...</td>\n",
" <td>再発又は難治性（R/R）MMの成人患者を対象にABBV-383の安全性及び薬物動態を検討する。</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2041...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>投与群：ABBV-383用量A\\n\\r\\nABBV-383の用量Aを151週間の試験期間中に...</td>\n",
" <td>Experimental: ABBV-383 Dose A\\n\\r\\nParticipant...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>4</th>\n",
" <td>jRCT2021240013</td>\n",
" <td>ノバルティスが実施した過去のサバトリマブ（MBG453）の試験を完了し，サバトリマブの継続投...</td>\n",
" <td>重篤な有害事象（SAE）及び有害事象（AE）を含めて，安全性を評価すること</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2021...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>サバトリマブ（MBG453）：静脈内投与\\n\\r\\nアザシチジン：皮下投与又は静脈内投与\\n...</td>\n",
" <td>Sabatolimab (MBG453): Solution for intravenous...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>5</th>\n",
" <td>jRCT2031240090</td>\n",
" <td>再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...</td>\n",
" <td>再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2031...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>無治療対照/標準治療対照</td>\n",
" <td>no treatment control/standard of care control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td>1）プロトコール治療無効と判断された場合（無効中止）\\n\\r\\n2）\\t有害事象によりプロト...</td>\n",
" <td>None</td>\n",
" <td>膠芽腫、grade 3・4星細胞腫、grade 3乏突起膠腫</td>\n",
" <td>glioblastoma, grade3/4 astrocytoma, grade3 oli...</td>\n",
" <td>A群：BPC療法\\n\\r\\n悪性神経膠腫に対して保険適用されている化学療法から患者の状態に合...</td>\n",
" <td>Group A: BPC Therapy\\n\\r\\nDepending on the pat...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>6</th>\n",
" <td>jRCT2031240014</td>\n",
" <td>自家幹細胞移植に非適応又は初回治療として自家幹細胞移植を予定していない未治療の多発性骨髄腫患...</td>\n",
" <td>本研究の目的は，teclistamabとダラツムマブ及びレナリドミドの併用（Tec-DR）並...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2031...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>active control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>Teclistamab -\\n\\r\\nTeclistamab，ダラツムマブ皮下投与製剤及びレ...</td>\n",
" <td>Teclistamab-Teclistamab, Daratumumab SC, Lenal...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>7</th>\n",
" <td>jRCT2041240003</td>\n",
" <td>再発又は難治性の多発性骨髄腫患者を対象に、AZD0305を単剤療法又は抗がん剤との併用療法と...</td>\n",
" <td>Treatment</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2041...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>AZD0305 を3週毎に静脈内投与する\\n</td>\n",
" <td>AZD0305 IV every 3 weeks\\n</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>8</th>\n",
" <td>jRCT2031230660</td>\n",
" <td>再発又は難治性多発性骨髄腫患者を対象とした，単剤療法としてのCevostamab及びCevo...</td>\n",
" <td>本試験は、再発または難治性の多発性骨髄腫（R/R MM）患者を対象に、Cevostamab単...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2031...</td>\n",
" <td>非無作為化比較</td>\n",
" <td>non-randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>cevostamab：Cevostamabは、1サイクルを28日間として2週間隔、4週間隔に...</td>\n",
" <td>cevostamab: Cevostamab will be administered in...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>9</th>\n",
" <td>jRCT2021230055</td>\n",
" <td>CD38 を標的とする前治療を受けた再発／難治性多発性骨髄腫患者を対象とした，エルラナタマブ...</td>\n",
" <td>再発または難治性多発性骨髄腫患者を対象に，エルラナタマブ単剤投与の有効性，安全性等を標準療法...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2021...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>active control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>エルラナタマブ（投与経路：皮下）\\n\\r\\nエロツズマブ（投与経路：静脈内）\\n\\r\\nポマ...</td>\n",
" <td>Drug: Elranatamab\\n\\r\\nElranatamab will be adm...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>10</th>\n",
" <td>jRCT2061230084</td>\n",
" <td>自家幹細胞移植後の奏効が不十分な初発多発性骨髄腫（NDMM）成人患者を対象とした、ideca...</td>\n",
" <td>自家幹細胞移植後の奏効が不十分なNDMM成人患者を対象に、ide-cel + LEN維持療法...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2061...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>active control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>A群\\n\\r\\n製品：イデカブタゲン ビクルユーセル\\n\\r\\n規定用量を規定された日に投与...</td>\n",
" <td>ArmA\\n\\r\\nBiological: idecabtagene vicleucel\\n...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>11</th>\n",
" <td>jRCT2071230097</td>\n",
" <td>再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480...</td>\n",
" <td>再発又は難治性多発性骨髄腫（RRMM）被験者を対象にmezigdomide（CC-92480...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2071...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>active control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>[日本人コホート] \\n\\r\\nMezigdomide/ボルテゾミブ/デキサメタゾン\\n\\r...</td>\n",
" <td>[Japan safety lead-in cohort]\\n\\r\\nMezigdomide...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>12</th>\n",
" <td>jRCT2071230095</td>\n",
" <td>再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480...</td>\n",
" <td>再発又は難治性多発性骨髄腫（RRMM）治験参加者を対象にmezigdomide、カルフィルゾ...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2071...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>active control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>A群：Mezigdomide、カルフィルゾミブ、デキサメタゾン\\n\\r\\nB群：カルフィルゾ...</td>\n",
" <td>Arm A: Mezigdomide, Carfilzomib and Dexamethas...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>13</th>\n",
" <td>jRCT2011230049</td>\n",
" <td>未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてIsatuximab､...</td>\n",
" <td>未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてのIsatuximab...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2011...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>治験治療、自家末梢血幹細胞採取および移植、血液検査、骨髄検査等</td>\n",
" <td>Study treatment,Autologous Peripheral Blood St...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>14</th>\n",
" <td>jRCT2051230108</td>\n",
" <td>再発及び難治性の多発性骨髄腫患者を対象としたBCMA x CD3 T細胞活性化抗体CC-93...</td>\n",
" <td>再発及び難治性の多発性骨髄腫の被験者でのCC-93269の安全性及び忍容性を評価する。</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2051...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>CC-93269</td>\n",
" <td>CC-93269</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>15</th>\n",
" <td>jRCT2051230069</td>\n",
" <td>神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...</td>\n",
" <td>神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2051...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td>1) 投与継続が困難な有害事象が発現した場合\\t\\n\\r\\n2) 治験開始後...</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>＜コホート1＞\\n\\r\\nロムスチン130 mg/m2を6週間ごとに経⼝投与する。\\n\\r\\...</td>\n",
" <td>&lt;cohort1&gt;\\n\\r\\nLomustine 130 mg/m2 orall...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>16</th>\n",
" <td>jRCT2031230223</td>\n",
" <td>新たに診断された多発性骨髄腫（NDMM）患者を対象として自家幹細胞移植（ASCT）後のibe...</td>\n",
" <td>新たに診断された多発性骨髄腫（NDMM）患者を対象として、自家幹細胞移植（ASCT）後のレナ...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2031...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>active control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>A1群: Iberdomide 用量 1レベル\\n\\r\\nA2群: Iberdomide 用...</td>\n",
" <td>Arm A1: Iberdomide Dose 1\\n\\r\\nArm A2: Iberdom...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>17</th>\n",
" <td>jRCT2051230065</td>\n",
" <td>多発性骨髄腫患者を対象として belantamab の単剤療法と他の治療との併用療法の安全性...</td>\n",
" <td>パート 1：3ライン以上の前治療を受けた（4L+）再発・難治性多発性骨髄腫（RRMM）患者を...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2051...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>active control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>パート1:\\n\\r\\n被験薬：Belantamab\\n\\r\\n被験薬：ベランタマブ マホドチ...</td>\n",
" <td>Part1:\\n\\r\\nDrug: Belantamab\\n\\r\\nDrug: Belant...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>18</th>\n",
" <td>jRCT2031230087</td>\n",
" <td>再発又は難治性の多発性骨髄腫患者を対象としたREGN5458（抗BCMA ⅹ 抗CD3二重特...</td>\n",
" <td>・本治験の第I相用量漸増パート：再発又は難治性MM患者を対象に、単剤療法としてのREGN54...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2031...</td>\n",
" <td>非無作為化比較</td>\n",
" <td>non-randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>被験薬: REGN5458静脈内投与\\n\\r\\n第II相: 疾患進行が認められるまで、又はそ...</td>\n",
" <td>Drug: REGN5458 administered by intravenous (IV...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>19</th>\n",
" <td>jRCT2032230060</td>\n",
" <td>初発IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多...</td>\n",
" <td>初発IDH野生型低悪性度神経膠腫を対象に、放射線化学療法後のテモゾロミド維持療法期における交...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2032...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td>以下のいずれかの場合、プロトコール治療（テモゾロミド維持療法6サイクル及びHeadG2）を中...</td>\n",
" <td>None</td>\n",
" <td>神経膠腫</td>\n",
" <td>Glioma</td>\n",
" <td>本品を使用する患者は、頭髪をすべて剃り、TTF ジェネレーターに接続した４枚のINE トラン...</td>\n",
" <td>The patient using the product should shave all...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>20</th>\n",
" <td>jRCT1070230005</td>\n",
" <td>迅速ウイルスPCR法によるウイルス感染症の早期診断</td>\n",
" <td>ウイルス感染疾患が疑われる患者について、検体を採取し、本診断法により①単純ヘルペスウイルス1...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT1070...</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td>白血病、悪性リンパ腫、多発性骨髄腫、再生不良性貧血、骨髄異形成症候群</td>\n",
" <td>Leukemia, malignant lymphoma, multiple myeloma...</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>観察研究</td>\n",
" <td>Observational</td>\n",
" </tr>\n",
" <tr>\n",
" <th>21</th>\n",
" <td>jRCT2031230009</td>\n",
" <td>先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療によるベネフィッ...</td>\n",
" <td>本治験は、先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療による...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2031...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>薬剤：イサツキシマブ IV（SAR650984）\\n\\r\\n 剤形：バイアル、投与経路：静脈...</td>\n",
" <td>Drug: Isatuximab IV (SAR650984)\\n\\r\\n Pharmace...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>22</th>\n",
" <td>jRCT2031230007</td>\n",
" <td>BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医...</td>\n",
" <td>BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫（コホート A...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2031...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td>1）\\t以下のいずれかによりプロトコール治療無効と判断された場合（無効中止）\\n\\r\\n①\\...</td>\n",
" <td>None</td>\n",
" <td>BRAF融合遺伝子、BRAF遺伝子再構成、低悪性度神経膠腫、膵癌</td>\n",
" <td>BRAF fusion gene, BRAF rearrangement, low-grad...</td>\n",
" <td>ビニメチニブとして1回45 mgを1日2回経口投与する。</td>\n",
" <td>Binimetinib is administered 45 mg orally, twic...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>23</th>\n",
" <td>jRCT2041220125</td>\n",
" <td>抗CD38 モノクローナル抗体及びレナリドミドを含む1～3 ラインの前治療歴がある再発又は難...</td>\n",
" <td>本試験の目的は，teclistamabの有効性をPVd/Kdと比較することである。</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2041...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>active control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>Teclistamab：被験者はteclistamab単剤療法を受ける。Teclistama...</td>\n",
" <td>Teclistamab: Participants will receive teclist...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>24</th>\n",
" <td>jRCT2021220036</td>\n",
" <td>MAGNETISMM-6：移植非適応の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF-...</td>\n",
" <td>本治験のパート 1 では多発性骨髄腫（MM）患者を対象として，エルラナタマブとダラツムマブお...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2021...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>active control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>パート1 用量レベル1：エルラナタマブ，ダラツムマブ，レナリドミド\\n\\r\\nパート1 用量...</td>\n",
" <td>Part 1 Dose Level 1:Elranatamab, Daratumumab, ...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>25</th>\n",
" <td>jRCT2063220071</td>\n",
" <td>移植適応のある初発の多発性骨髄腫被験者を対象としたダラツムマブ，ボルテゾミブ，レナリドミド及...</td>\n",
" <td>無増悪生存期間（PFS）及び持続的微小残存病変（MRD）陰性complete respons...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2063...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>active control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>・A群（DVRd導入療法 + ASCT + DVRd地固め療法 + レナリドミド維持療法）\\...</td>\n",
" <td>- Arm A (DVRd Induction + ASCT + DVRd Consolid...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>26</th>\n",
" <td>jRCT2021220022</td>\n",
" <td>[M22-947] 再発又は難治性多発性骨髄腫患者を対象とした薬物治療レジメンを併用したAB...</td>\n",
" <td>再発又は難治性多発性骨髄腫患者を対象にポマリドミド-デキサメタソン（Pd），レナリドミド-デ...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2021...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>1サイクルを28日間とし，ABBV-383（静脈内投与）とポマリドミド（経口）+デキサメタゾ...</td>\n",
" <td>Participants will receive intravenous (IV) ABB...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>27</th>\n",
" <td>jRCT2033220220</td>\n",
" <td>Ciltacabtagene autoleucel の投与を受けた患者を対象とした長期追跡調査試験</td>\n",
" <td>この試験の目的は、ciltacabtagene autoleucel(Cilta-cel)投...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2033...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>Cilta-cel：本試験は、先行試験でcilta-celの投与を受けた被験者に対する追跡調...</td>\n",
" <td>Cilta-cel:Participants who had received cilta-...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>28</th>\n",
" <td>jRCT2031220060</td>\n",
" <td>自家造血幹細胞移植後の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF 06863135...</td>\n",
" <td>自家造血幹細胞移植後に初発多発性骨髄腫患者を対象として，PF-06863135の単剤投与がレ...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2031...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>active control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>Elranatamab \\n\\r\\nBCMAおよびCD3を標的とする二重特異性抗体\\n\\r\\...</td>\n",
" <td>Drug: Elranatamab \\n\\r\\nBCMA-CD3 bispecific an...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>29</th>\n",
" <td>jRCTs051220019</td>\n",
" <td>再発悪性神経膠腫に対するホウ素中性子捕捉療法で生じる腫瘍局所の早期反応のPETによる探索</td>\n",
" <td>BNCT(Boron Neutron Capture Therapy：ホウ素中性子捕捉療法)...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCTs051...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td>・BNCT実施の中止：\\n\\r\\n同意取得に到った後に、選択基準に背馳する事象、または除外基...</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>標準治療後の再発悪性神経膠腫の患者を対象に、サイクロトロン中性子照射システム（NeuCure...</td>\n",
" <td>BNCT is performed in combination with a cyclot...</td>\n",
" <td>介入研究</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" <tr>\n",
" <th>30</th>\n",
" <td>jRCT2053220006</td>\n",
" <td>製品規格に適合しないIDECABTAGENE VICLEUCELを被験者に投与する拡大アクセ...</td>\n",
" <td>本治験の主要目的は、不適合ide-celの安全性を評価することである。</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2053...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>ide-celの添付文書、治験実施医療機関の通常診療慣行に従い、また担当医師の判断に基づき、...</td>\n",
" <td>In accordance with the ide-cel prescribing inf...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>31</th>\n",
" <td>jRCT2031210635</td>\n",
" <td>再発又は難治性多発性骨髄腫患者を対象としてteclistamabとダラツムマブ皮下投与製剤の...</td>\n",
" <td>本治験の目的は，teclistamab とダラツムマブ皮下投与製剤（SC）の併用（Tec-D...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2031...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>active control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>ダラツムマブ\\n\\r\\nA群:Teclistamab-ダラツムマブ（Tec-Dara）\\n\\...</td>\n",
" <td>Daratumumab\\n\\r\\nArm A: Teclistamab-daratumuma...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>32</th>\n",
" <td>jRCT2031210607</td>\n",
" <td>有効な治療法がない又は他の治療法が適さない再発・難治性多発性骨髄腫患者を対象としたベランタマ...</td>\n",
" <td>既存の治療法でベネフィットが得られず、進行中又は実施予定の本剤の臨床試験に適格でなく、かつ適...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2031...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>被験薬：Belantamab mafodotin（ヒト化抗BCMAモノクローナル抗体）\\n\\...</td>\n",
" <td>Belantamab mafodotin (anti-BCMA (B-cell matura...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>33</th>\n",
" <td>jRCT2033210469</td>\n",
" <td>デリタクト注使用成績比較調査</td>\n",
" <td>使用実態下におけるデリタクト注の悪性神経膠腫患者に対する安全性及び有効性を確認することを目的...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2033...</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>34</th>\n",
" <td>jRCTs071210084</td>\n",
" <td>未治療の高齢多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間で...</td>\n",
" <td>未治療の高齢者多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCTs071...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td>1) 原病の増悪が認められた場合もしくは治療効果なしと判断された場合\\n\\r\\n2) 次...</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>1. ダラツムマブ+レナリドミド+デキサメサゾン併用寛解導入療法 (DRD療法)\\n\\r\\n...</td>\n",
" <td>1. Daratumumab + lenalidomide + dexamethasone ...</td>\n",
" <td>介入研究</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" <tr>\n",
" <th>35</th>\n",
" <td>jRCTs071210074</td>\n",
" <td>未治療多発性骨髄腫に対するダラツムマブ、レナリドミドおよびデキサメタゾン療法に治療奏効で層別...</td>\n",
" <td>未治療多発性骨髄腫に対し、ダラツムマブ、レナリドミドおよびデキサメサゾン投与による寛解導入療...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCTs071...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td>1) 原病の増悪が認められた場合もしくは治療効果なしと判断された場合\\n\\r\\n2) 次...</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>1)寛解導入療法\\n\\r\\nDRD療法 1,2コース:Dara IV 16mg/kg or ...</td>\n",
" <td>1) Induction therapy\\n\\r\\nDRD therapy 1,2 cour...</td>\n",
" <td>介入研究</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" <tr>\n",
" <th>36</th>\n",
" <td>jRCT2031210299</td>\n",
" <td>再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験</td>\n",
" <td>再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2031...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>DSP-0390を1日1回経口投与する。1サイクルを28日間とし、安全性及び治療レスポンスを...</td>\n",
" <td>Patients will receive DSP-0390 orally once dai...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>37</th>\n",
" <td>jRCT2011210025</td>\n",
" <td>造血幹細胞移植の適応とならない初発の多発性骨髄腫患者を対象として，ボルテゾミブ，レナリドミド...</td>\n",
" <td>造血幹細胞移植が適応とならない初発の多発性骨髄腫患者において，VRd 導入療法後にJNJ-6...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2011...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>active control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>A群\\n\\r\\n被験者は，ランダム化を行う前にボルテゾミブ，レナリドミド及びデキサメタゾン(...</td>\n",
" <td>Arm A\\n\\r\\nParticipants will receive bortezomi...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>38</th>\n",
" <td>jRCT2051210043</td>\n",
" <td>再発又は難治性の多発性骨髄腫（RRMM）患者を対象にiberdomide、ダラツムマブ及びデ...</td>\n",
" <td>再発又は難治性の多発性骨髄腫（RRMM）患者を対象に無増悪生存期間（PFS）についてiber...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2051...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>active control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>【IberDd】第1ステージにおいて、Iberdomide（CC-220）1.0mg、1.3...</td>\n",
" <td>[IberDd] At the First Stage, Iberdomide (CC-22...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>39</th>\n",
" <td>jRCTs031200320</td>\n",
" <td>JCOG1911: 高齢者または移植拒否若年者の未治療多発性骨髄腫患者に対するダラツムマブ＋...</td>\n",
" <td>高齢または移植拒否若年の未治療多発性骨髄腫患者に対するダラツムマブ＋メルファラン＋プレドニゾ...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCTs031...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>active control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td>＜患者の中止について＞\\n\\r\\nD-MPB療法の中止規準\\n\\r\\n（1）\\tD-MPB療...</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>導入療法（A・B群共通）：D-MPB療法（3週1コースとして合計18コース行う）、第1コース...</td>\n",
" <td>Induction therapy (both arm A and arm B) D-MPB...</td>\n",
" <td>介入研究</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" <tr>\n",
" <th>40</th>\n",
" <td>jRCT2033200278</td>\n",
" <td>MMG49 抗原陽性の再発・難治性多発性骨髄腫患者を対象に OPC-415 の安全性及び有効...</td>\n",
" <td>【第 I 相部分】\\r\\n• 骨髄腫細胞特異的抗体（ MMG49）抗原陽性の再発・難治性のM...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCT2033...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>OPC-415 (上限1×10^7個/kg), 2日間投与\\n</td>\n",
" <td>OPC-415 (up to 1X10^7cells/kg)\\n\\r\\nOn 2 days\\...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>41</th>\n",
" <td>jRCTs071190010</td>\n",
" <td>悪性神経膠腫に対する高圧酸素療法、メマンチン塩酸塩併用放射線化学治療：第Ⅲ相ランダム化比較試験</td>\n",
" <td>悪性神経膠腫患者に対する放射線照射療法によって引き起こされる認知機能低下が、メマンチン塩酸塩...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCTs071...</td>\n",
" <td>無作為化比較</td>\n",
" <td>randomized controlled trial</td>\n",
" <td>二重盲検</td>\n",
" <td>double blind</td>\n",
" <td>プラセボ対照</td>\n",
" <td>placebo control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td>CTCAE v4.0 Grade 1-2の場合は、メマンチン塩酸塩内服の継続・増量可とし、G...</td>\n",
" <td>None</td>\n",
" <td>膠芽腫、退形成性星細胞腫、退形成性乏突起膠腫</td>\n",
" <td>gliobalastoma, anaplastic astrocytoma,anaplast...</td>\n",
" <td>プロトコル治療は放射線照射療法の適用が決定次第、開始される。プロトコル治療の併用療法として、...</td>\n",
" <td>1)Arm A: Patients randomly selected group have...</td>\n",
" <td>介入研究</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" <tr>\n",
" <th>42</th>\n",
" <td>jRCTs021180010</td>\n",
" <td>塩酸ニムスチン(ACNU)を用いたconvection enhanced delivery法...</td>\n",
" <td>悪性脊髄神経膠腫に対する塩酸ニムスチンを用いたconvection enhanced del...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCTs021...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>無治療対照/標準治療対照</td>\n",
" <td>no treatment control/standard of care control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td>以下のいずれかの場合プロトコール治療中止とする。\\n\\r\\n(ア)\\t後述する有害事象により...</td>\n",
" <td>None</td>\n",
" <td>脊髄腫瘍</td>\n",
" <td>Spinal cord tumor</td>\n",
" <td>ACNU（0.25 mg/ml, 4ml）のCED法による脊髄髄内注入\\n\\r\\nテモゾロミ...</td>\n",
" <td>ACNU delivery (0.25 mg/ml, 4ml) into the spin...</td>\n",
" <td>介入研究</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" <tr>\n",
" <th>43</th>\n",
" <td>jRCTs061180085</td>\n",
" <td>初発悪性神経膠腫に対する手術、術後放射線治療およびTemozolomide併用の標準治療と、...</td>\n",
" <td>初発悪性神経膠腫において手術、放射線治療およびTemozolomideを受ける、化学療法未施...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCTs061...</td>\n",
" <td>非無作為化比較</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>非対照</td>\n",
" <td>uncontrolled control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td>非血液毒性\\n\\r\\n1)試験薬投与後、投与前と比較して症状の悪化または臨床検査値の異常変動...</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>1）WT1-W10ペプチド癌ワクチン療法\\n\\r\\nWT1-W10ペプチド癌ワクチン療法とし...</td>\n",
" <td>1)\\tWT1-W10 peptide immunotherapy\\n\\r\\nIntrade...</td>\n",
" <td>介入研究</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" <tr>\n",
" <th>44</th>\n",
" <td>jRCTs031180170</td>\n",
" <td>初発悪性神経膠腫に対するVEGFR1/2ペプチドワクチンの第I/II相臨床試験</td>\n",
" <td>初発悪性神経膠腫に対するVEGFR1/2由来のHLA-A*2402拘束性エピトープペプチドを...</td>\n",
" <td>https://jrct.niph.go.jp/latest-detail/jRCTs031...</td>\n",
" <td>単一群</td>\n",
" <td>single arm study</td>\n",
" <td>非盲検</td>\n",
" <td>open(masking not used)</td>\n",
" <td>ヒストリカルコントロール</td>\n",
" <td>historical control</td>\n",
" <td>...</td>\n",
" <td>男性・女性</td>\n",
" <td>Both</td>\n",
" <td>症例登録の中止\\n\\r\\n1)原疾患の増悪\\n\\r\\n2)治療を中止すべき重篤な有害事象の発...</td>\n",
" <td>None</td>\n",
" <td>悪性神経膠腫</td>\n",
" <td>Malignant glioma</td>\n",
" <td>VEGFR1およびVEGFR2ペプチド(各2mg)とIFA混合液の皮下投与。毎週投与８回後、...</td>\n",
" <td>Subcutaneous injection of VEGFR1 and VEGFR2 pe...</td>\n",
" <td>介入研究</td>\n",
" <td>Interventional</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"<p>45 rows × 32 columns</p>\n",
"</div>"
],
"text/plain": [
" JRCT ID Title \\\n",
"0 jRCT2051240141 新たに診断され放射線療法を完了したH3 K27M変異を有するびまん性神経膠腫の治療のためのO... \n",
"1 jRCT2051240121 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ... \n",
"2 jRCT1031240239 JCOG2303: 可及的摘出されたIDH変異型星細胞腫の術後化学放射線療法に対する待機化学... \n",
"3 jRCT2041240056 [M23-001] 再発性又は難治性多発性骨髄腫患者を対象にABBV-383 を皮下投与する... \n",
"4 jRCT2021240013 ノバルティスが実施した過去のサバトリマブ（MBG453）の試験を完了し，サバトリマブの継続投... \n",
"5 jRCT2031240090 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... \n",
"6 jRCT2031240014 自家幹細胞移植に非適応又は初回治療として自家幹細胞移植を予定していない未治療の多発性骨髄腫患... \n",
"7 jRCT2041240003 再発又は難治性の多発性骨髄腫患者を対象に、AZD0305を単剤療法又は抗がん剤との併用療法と... \n",
"8 jRCT2031230660 再発又は難治性多発性骨髄腫患者を対象とした，単剤療法としてのCevostamab及びCevo... \n",
"9 jRCT2021230055 CD38 を標的とする前治療を受けた再発／難治性多発性骨髄腫患者を対象とした，エルラナタマブ... \n",
"10 jRCT2061230084 自家幹細胞移植後の奏効が不十分な初発多発性骨髄腫（NDMM）成人患者を対象とした、ideca... \n",
"11 jRCT2071230097 再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480... \n",
"12 jRCT2071230095 再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480... \n",
"13 jRCT2011230049 未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてIsatuximab､... \n",
"14 jRCT2051230108 再発及び難治性の多発性骨髄腫患者を対象としたBCMA x CD3 T細胞活性化抗体CC-93... \n",
"15 jRCT2051230069 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... \n",
"16 jRCT2031230223 新たに診断された多発性骨髄腫（NDMM）患者を対象として自家幹細胞移植（ASCT）後のibe... \n",
"17 jRCT2051230065 多発性骨髄腫患者を対象として belantamab の単剤療法と他の治療との併用療法の安全性... \n",
"18 jRCT2031230087 再発又は難治性の多発性骨髄腫患者を対象としたREGN5458（抗BCMA ⅹ 抗CD3二重特... \n",
"19 jRCT2032230060 初発IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多... \n",
"20 jRCT1070230005 迅速ウイルスPCR法によるウイルス感染症の早期診断 \n",
"21 jRCT2031230009 先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療によるベネフィッ... \n",
"22 jRCT2031230007 BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医... \n",
"23 jRCT2041220125 抗CD38 モノクローナル抗体及びレナリドミドを含む1～3 ラインの前治療歴がある再発又は難... \n",
"24 jRCT2021220036 MAGNETISMM-6：移植非適応の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF-... \n",
"25 jRCT2063220071 移植適応のある初発の多発性骨髄腫被験者を対象としたダラツムマブ，ボルテゾミブ，レナリドミド及... \n",
"26 jRCT2021220022 [M22-947] 再発又は難治性多発性骨髄腫患者を対象とした薬物治療レジメンを併用したAB... \n",
"27 jRCT2033220220 Ciltacabtagene autoleucel の投与を受けた患者を対象とした長期追跡調査試験 \n",
"28 jRCT2031220060 自家造血幹細胞移植後の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF 06863135... \n",
"29 jRCTs051220019 再発悪性神経膠腫に対するホウ素中性子捕捉療法で生じる腫瘍局所の早期反応のPETによる探索 \n",
"30 jRCT2053220006 製品規格に適合しないIDECABTAGENE VICLEUCELを被験者に投与する拡大アクセ... \n",
"31 jRCT2031210635 再発又は難治性多発性骨髄腫患者を対象としてteclistamabとダラツムマブ皮下投与製剤の... \n",
"32 jRCT2031210607 有効な治療法がない又は他の治療法が適さない再発・難治性多発性骨髄腫患者を対象としたベランタマ... \n",
"33 jRCT2033210469 デリタクト注使用成績比較調査 \n",
"34 jRCTs071210084 未治療の高齢多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間で... \n",
"35 jRCTs071210074 未治療多発性骨髄腫に対するダラツムマブ、レナリドミドおよびデキサメタゾン療法に治療奏効で層別... \n",
"36 jRCT2031210299 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 \n",
"37 jRCT2011210025 造血幹細胞移植の適応とならない初発の多発性骨髄腫患者を対象として，ボルテゾミブ，レナリドミド... \n",
"38 jRCT2051210043 再発又は難治性の多発性骨髄腫（RRMM）患者を対象にiberdomide、ダラツムマブ及びデ... \n",
"39 jRCTs031200320 JCOG1911: 高齢者または移植拒否若年者の未治療多発性骨髄腫患者に対するダラツムマブ＋... \n",
"40 jRCT2033200278 MMG49 抗原陽性の再発・難治性多発性骨髄腫患者を対象に OPC-415 の安全性及び有効... \n",
"41 jRCTs071190010 悪性神経膠腫に対する高圧酸素療法、メマンチン塩酸塩併用放射線化学治療：第Ⅲ相ランダム化比較試験 \n",
"42 jRCTs021180010 塩酸ニムスチン(ACNU)を用いたconvection enhanced delivery法... \n",
"43 jRCTs061180085 初発悪性神経膠腫に対する手術、術後放射線治療およびTemozolomide併用の標準治療と、... \n",
"44 jRCTs031180170 初発悪性神経膠腫に対するVEGFR1/2ペプチドワクチンの第I/II相臨床試験 \n",
"\n",
" 研究・治験の目的 \\\n",
"0 H3 K27M変異びまん性神経膠腫を有する被験者を対象に、放射線療法後に投与されたONC20... \n",
"1 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... \n",
"2 手術で可及的摘出（90%以上の摘出）されたIDH変異型星細胞腫Grade 3を対象に、標準治... \n",
"3 再発又は難治性（R/R）MMの成人患者を対象にABBV-383の安全性及び薬物動態を検討する。 \n",
"4 重篤な有害事象（SAE）及び有害事象（AE）を含めて，安全性を評価すること \n",
"5 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl... \n",
"6 本研究の目的は，teclistamabとダラツムマブ及びレナリドミドの併用（Tec-DR）並... \n",
"7 Treatment \n",
"8 本試験は、再発または難治性の多発性骨髄腫（R/R MM）患者を対象に、Cevostamab単... \n",
"9 再発または難治性多発性骨髄腫患者を対象に，エルラナタマブ単剤投与の有効性，安全性等を標準療法... \n",
"10 自家幹細胞移植後の奏効が不十分なNDMM成人患者を対象に、ide-cel + LEN維持療法... \n",
"11 再発又は難治性多発性骨髄腫（RRMM）被験者を対象にmezigdomide（CC-92480... \n",
"12 再発又は難治性多発性骨髄腫（RRMM）治験参加者を対象にmezigdomide、カルフィルゾ... \n",
"13 未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてのIsatuximab... \n",
"14 再発及び難治性の多発性骨髄腫の被験者でのCC-93269の安全性及び忍容性を評価する。 \n",
"15 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... \n",
"16 新たに診断された多発性骨髄腫（NDMM）患者を対象として、自家幹細胞移植（ASCT）後のレナ... \n",
"17 パート 1：3ライン以上の前治療を受けた（4L+）再発・難治性多発性骨髄腫（RRMM）患者を... \n",
"18 ・本治験の第I相用量漸増パート：再発又は難治性MM患者を対象に、単剤療法としてのREGN54... \n",
"19 初発IDH野生型低悪性度神経膠腫を対象に、放射線化学療法後のテモゾロミド維持療法期における交... \n",
"20 ウイルス感染疾患が疑われる患者について、検体を採取し、本診断法により①単純ヘルペスウイルス1... \n",
"21 本治験は、先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療による... \n",
"22 BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫（コホート A... \n",
"23 本試験の目的は，teclistamabの有効性をPVd/Kdと比較することである。 \n",
"24 本治験のパート 1 では多発性骨髄腫（MM）患者を対象として，エルラナタマブとダラツムマブお... \n",
"25 無増悪生存期間（PFS）及び持続的微小残存病変（MRD）陰性complete respons... \n",
"26 再発又は難治性多発性骨髄腫患者を対象にポマリドミド-デキサメタソン（Pd），レナリドミド-デ... \n",
"27 この試験の目的は、ciltacabtagene autoleucel(Cilta-cel)投... \n",
"28 自家造血幹細胞移植後に初発多発性骨髄腫患者を対象として，PF-06863135の単剤投与がレ... \n",
"29 BNCT(Boron Neutron Capture Therapy：ホウ素中性子捕捉療法)... \n",
"30 本治験の主要目的は、不適合ide-celの安全性を評価することである。 \n",
"31 本治験の目的は，teclistamab とダラツムマブ皮下投与製剤（SC）の併用（Tec-D... \n",
"32 既存の治療法でベネフィットが得られず、進行中又は実施予定の本剤の臨床試験に適格でなく、かつ適... \n",
"33 使用実態下におけるデリタクト注の悪性神経膠腫患者に対する安全性及び有効性を確認することを目的... \n",
"34 未治療の高齢者多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間... \n",
"35 未治療多発性骨髄腫に対し、ダラツムマブ、レナリドミドおよびデキサメサゾン投与による寛解導入療... \n",
"36 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... \n",
"37 造血幹細胞移植が適応とならない初発の多発性骨髄腫患者において，VRd 導入療法後にJNJ-6... \n",
"38 再発又は難治性の多発性骨髄腫（RRMM）患者を対象に無増悪生存期間（PFS）についてiber... \n",
"39 高齢または移植拒否若年の未治療多発性骨髄腫患者に対するダラツムマブ＋メルファラン＋プレドニゾ... \n",
"40 【第 I 相部分】\\r\\n• 骨髄腫細胞特異的抗体（ MMG49）抗原陽性の再発・難治性のM... \n",
"41 悪性神経膠腫患者に対する放射線照射療法によって引き起こされる認知機能低下が、メマンチン塩酸塩... \n",
"42 悪性脊髄神経膠腫に対する塩酸ニムスチンを用いたconvection enhanced del... \n",
"43 初発悪性神経膠腫において手術、放射線治療およびTemozolomideを受ける、化学療法未施... \n",
"44 初発悪性神経膠腫に対するVEGFR1/2由来のHLA-A*2402拘束性エピトープペプチドを... \n",
"\n",
" URL 無作為化 \\\n",
"0 https://jrct.niph.go.jp/latest-detail/jRCT2051... 無作為化比較 \n",
"1 https://jrct.niph.go.jp/latest-detail/jRCT2051... 無作為化比較 \n",
"2 https://jrct.niph.go.jp/latest-detail/jRCT1031... 無作為化比較 \n",
"3 https://jrct.niph.go.jp/latest-detail/jRCT2041... 単一群 \n",
"4 https://jrct.niph.go.jp/latest-detail/jRCT2021... 単一群 \n",
"5 https://jrct.niph.go.jp/latest-detail/jRCT2031... 無作為化比較 \n",
"6 https://jrct.niph.go.jp/latest-detail/jRCT2031... 無作為化比較 \n",
"7 https://jrct.niph.go.jp/latest-detail/jRCT2041... 単一群 \n",
"8 https://jrct.niph.go.jp/latest-detail/jRCT2031... 非無作為化比較 \n",
"9 https://jrct.niph.go.jp/latest-detail/jRCT2021... 無作為化比較 \n",
"10 https://jrct.niph.go.jp/latest-detail/jRCT2061... 無作為化比較 \n",
"11 https://jrct.niph.go.jp/latest-detail/jRCT2071... 無作為化比較 \n",
"12 https://jrct.niph.go.jp/latest-detail/jRCT2071... 無作為化比較 \n",
"13 https://jrct.niph.go.jp/latest-detail/jRCT2011... 単一群 \n",
"14 https://jrct.niph.go.jp/latest-detail/jRCT2051... 単一群 \n",
"15 https://jrct.niph.go.jp/latest-detail/jRCT2051... 単一群 \n",
"16 https://jrct.niph.go.jp/latest-detail/jRCT2031... 無作為化比較 \n",
"17 https://jrct.niph.go.jp/latest-detail/jRCT2051... 無作為化比較 \n",
"18 https://jrct.niph.go.jp/latest-detail/jRCT2031... 非無作為化比較 \n",
"19 https://jrct.niph.go.jp/latest-detail/jRCT2032... 単一群 \n",
"20 https://jrct.niph.go.jp/latest-detail/jRCT1070... \n",
"21 https://jrct.niph.go.jp/latest-detail/jRCT2031... 単一群 \n",
"22 https://jrct.niph.go.jp/latest-detail/jRCT2031... 単一群 \n",
"23 https://jrct.niph.go.jp/latest-detail/jRCT2041... 無作為化比較 \n",
"24 https://jrct.niph.go.jp/latest-detail/jRCT2021... 無作為化比較 \n",
"25 https://jrct.niph.go.jp/latest-detail/jRCT2063... 無作為化比較 \n",
"26 https://jrct.niph.go.jp/latest-detail/jRCT2021... 単一群 \n",
"27 https://jrct.niph.go.jp/latest-detail/jRCT2033... 単一群 \n",
"28 https://jrct.niph.go.jp/latest-detail/jRCT2031... 無作為化比較 \n",
"29 https://jrct.niph.go.jp/latest-detail/jRCTs051... 単一群 \n",
"30 https://jrct.niph.go.jp/latest-detail/jRCT2053... 単一群 \n",
"31 https://jrct.niph.go.jp/latest-detail/jRCT2031... 無作為化比較 \n",
"32 https://jrct.niph.go.jp/latest-detail/jRCT2031... 単一群 \n",
"33 https://jrct.niph.go.jp/latest-detail/jRCT2033... \n",
"34 https://jrct.niph.go.jp/latest-detail/jRCTs071... 単一群 \n",
"35 https://jrct.niph.go.jp/latest-detail/jRCTs071... 単一群 \n",
"36 https://jrct.niph.go.jp/latest-detail/jRCT2031... 単一群 \n",
"37 https://jrct.niph.go.jp/latest-detail/jRCT2011... 無作為化比較 \n",
"38 https://jrct.niph.go.jp/latest-detail/jRCT2051... 無作為化比較 \n",
"39 https://jrct.niph.go.jp/latest-detail/jRCTs031... 無作為化比較 \n",
"40 https://jrct.niph.go.jp/latest-detail/jRCT2033... 単一群 \n",
"41 https://jrct.niph.go.jp/latest-detail/jRCTs071... 無作為化比較 \n",
"42 https://jrct.niph.go.jp/latest-detail/jRCTs021... 単一群 \n",
"43 https://jrct.niph.go.jp/latest-detail/jRCTs061... 非無作為化比較 \n",
"44 https://jrct.niph.go.jp/latest-detail/jRCTs031... 単一群 \n",
"\n",
" allocation 盲検化 masking \\\n",
"0 randomized controlled trial 二重盲検 double blind \n",
"1 randomized controlled trial 非盲検 open(masking not used) \n",
"2 randomized controlled trial 非盲検 open(masking not used) \n",
"3 single arm study 非盲検 open(masking not used) \n",
"4 single arm study 非盲検 open(masking not used) \n",
"5 randomized controlled trial 非盲検 open(masking not used) \n",
"6 randomized controlled trial 非盲検 open(masking not used) \n",
"7 single arm study 非盲検 open(masking not used) \n",
"8 non-randomized controlled trial 非盲検 open(masking not used) \n",
"9 randomized controlled trial 非盲検 open(masking not used) \n",
"10 randomized controlled trial 非盲検 open(masking not used) \n",
"11 randomized controlled trial 非盲検 open(masking not used) \n",
"12 randomized controlled trial 非盲検 open(masking not used) \n",
"13 single arm study 非盲検 open(masking not used) \n",
"14 single arm study 非盲検 open(masking not used) \n",
"15 single arm study 非盲検 open(masking not used) \n",
"16 randomized controlled trial 非盲検 open(masking not used) \n",
"17 randomized controlled trial 非盲検 open(masking not used) \n",
"18 non-randomized controlled trial 非盲検 open(masking not used) \n",
"19 single arm study 非盲検 open(masking not used) \n",
"20 \n",
"21 single arm study 非盲検 open(masking not used) \n",
"22 single arm study 非盲検 open(masking not used) \n",
"23 randomized controlled trial 非盲検 open(masking not used) \n",
"24 randomized controlled trial 非盲検 open(masking not used) \n",
"25 randomized controlled trial 非盲検 open(masking not used) \n",
"26 single arm study 非盲検 open(masking not used) \n",
"27 single arm study 非盲検 open(masking not used) \n",
"28 randomized controlled trial 非盲検 open(masking not used) \n",
"29 single arm study 非盲検 open(masking not used) \n",
"30 single arm study 非盲検 open(masking not used) \n",
"31 randomized controlled trial 非盲検 open(masking not used) \n",
"32 single arm study 非盲検 open(masking not used) \n",
"33 \n",
"34 single arm study 非盲検 open(masking not used) \n",
"35 single arm study 非盲検 open(masking not used) \n",
"36 single arm study 非盲検 open(masking not used) \n",
"37 randomized controlled trial 非盲検 open(masking not used) \n",
"38 randomized controlled trial 非盲検 open(masking not used) \n",
"39 randomized controlled trial 非盲検 open(masking not used) \n",
"40 single arm study 非盲検 open(masking not used) \n",
"41 randomized controlled trial 二重盲検 double blind \n",
"42 single arm study 非盲検 open(masking not used) \n",
"43 single arm study 非盲検 open(masking not used) \n",
"44 single arm study 非盲検 open(masking not used) \n",
"\n",
" 対照 control ... 性別 \\\n",
"0 プラセボ対照 placebo control ... \n",
"1 実薬（治療）対照 active control ... \n",
"2 実薬（治療）対照 active control ... 男性・女性 \n",
"3 非対照 uncontrolled control ... \n",
"4 非対照 uncontrolled control ... 男性・女性 \n",
"5 無治療対照/標準治療対照 no treatment control/standard of care control ... 男性・女性 \n",
"6 実薬（治療）対照 active control ... 男性・女性 \n",
"7 非対照 uncontrolled control ... 男性・女性 \n",
"8 非対照 uncontrolled control ... 男性・女性 \n",
"9 実薬（治療）対照 active control ... 男性・女性 \n",
"10 実薬（治療）対照 active control ... 男性・女性 \n",
"11 実薬（治療）対照 active control ... 男性・女性 \n",
"12 実薬（治療）対照 active control ... 男性・女性 \n",
"13 非対照 uncontrolled control ... 男性・女性 \n",
"14 非対照 uncontrolled control ... 男性・女性 \n",
"15 非対照 uncontrolled control ... 男性・女性 \n",
"16 実薬（治療）対照 active control ... 男性・女性 \n",
"17 実薬（治療）対照 active control ... 男性・女性 \n",
"18 非対照 uncontrolled control ... 男性・女性 \n",
"19 非対照 uncontrolled control ... 男性・女性 \n",
"20 ... 男性・女性 \n",
"21 非対照 uncontrolled control ... 男性・女性 \n",
"22 非対照 uncontrolled control ... 男性・女性 \n",
"23 実薬（治療）対照 active control ... 男性・女性 \n",
"24 実薬（治療）対照 active control ... 男性・女性 \n",
"25 実薬（治療）対照 active control ... 男性・女性 \n",
"26 非対照 uncontrolled control ... 男性・女性 \n",
"27 非対照 uncontrolled control ... 男性・女性 \n",
"28 実薬（治療）対照 active control ... 男性・女性 \n",
"29 非対照 uncontrolled control ... 男性・女性 \n",
"30 非対照 uncontrolled control ... 男性・女性 \n",
"31 実薬（治療）対照 active control ... 男性・女性 \n",
"32 非対照 uncontrolled control ... 男性・女性 \n",
"33 ... 男性・女性 \n",
"34 非対照 uncontrolled control ... 男性・女性 \n",
"35 非対照 uncontrolled control ... 男性・女性 \n",
"36 非対照 uncontrolled control ... 男性・女性 \n",
"37 実薬（治療）対照 active control ... 男性・女性 \n",
"38 実薬（治療）対照 active control ... 男性・女性 \n",
"39 実薬（治療）対照 active control ... 男性・女性 \n",
"40 非対照 uncontrolled control ... 男性・女性 \n",
"41 プラセボ対照 placebo control ... 男性・女性 \n",
"42 無治療対照/標準治療対照 no treatment control/standard of care control ... 男性・女性 \n",
"43 非対照 uncontrolled control ... 男性・女性 \n",
"44 ヒストリカルコントロール historical control ... 男性・女性 \n",
"\n",
" Gender 中止基準 \\\n",
"0 \n",
"1 \n",
"2 Both ＜患者の中止について＞\\n\\r\\n(1) プロトコール治療無効と判断\\n\\r\\n(2) 有害... \n",
"3 \n",
"4 Both \n",
"5 Both 1）プロトコール治療無効と判断された場合（無効中止）\\n\\r\\n2）\\t有害事象によりプロト... \n",
"6 Both \n",
"7 Both \n",
"8 Both \n",
"9 Both \n",
"10 Both \n",
"11 Both \n",
"12 Both \n",
"13 Both \n",
"14 Both \n",
"15 Both 1) 投与継続が困難な有害事象が発現した場合\\t\\n\\r\\n2) 治験開始後... \n",
"16 Both \n",
"17 Both \n",
"18 Both \n",
"19 Both 以下のいずれかの場合、プロトコール治療（テモゾロミド維持療法6サイクル及びHeadG2）を中... \n",
"20 Both \n",
"21 Both \n",
"22 Both 1）\\t以下のいずれかによりプロトコール治療無効と判断された場合（無効中止）\\n\\r\\n①\\... \n",
"23 Both \n",
"24 Both \n",
"25 Both \n",
"26 Both \n",
"27 Both \n",
"28 Both \n",
"29 Both ・BNCT実施の中止：\\n\\r\\n同意取得に到った後に、選択基準に背馳する事象、または除外基... \n",
"30 Both \n",
"31 Both \n",
"32 Both \n",
"33 Both \n",
"34 Both 1) 原病の増悪が認められた場合もしくは治療効果なしと判断された場合\\n\\r\\n2) 次... \n",
"35 Both 1) 原病の増悪が認められた場合もしくは治療効果なしと判断された場合\\n\\r\\n2) 次... \n",
"36 Both \n",
"37 Both \n",
"38 Both \n",
"39 Both ＜患者の中止について＞\\n\\r\\nD-MPB療法の中止規準\\n\\r\\n（1）\\tD-MPB療... \n",
"40 Both \n",
"41 Both CTCAE v4.0 Grade 1-2の場合は、メマンチン塩酸塩内服の継続・増量可とし、G... \n",
"42 Both 以下のいずれかの場合プロトコール治療中止とする。\\n\\r\\n(ア)\\t後述する有害事象により... \n",
"43 Both 非血液毒性\\n\\r\\n1)試験薬投与後、投与前と比較して症状の悪化または臨床検査値の異常変動... \n",
"44 Both 症例登録の中止\\n\\r\\n1)原疾患の増悪\\n\\r\\n2)治療を中止すべき重篤な有害事象の発... \n",
"\n",
" Discontinuation Criteria 対象疾患キーワード \\\n",
"0 None \n",
"1 None \n",
"2 None \n",
"3 None \n",
"4 None \n",
"5 None 膠芽腫、grade 3・4星細胞腫、grade 3乏突起膠腫 \n",
"6 None \n",
"7 None \n",
"8 None \n",
"9 None \n",
"10 None \n",
"11 None \n",
"12 None \n",
"13 None \n",
"14 None \n",
"15 None \n",
"16 None \n",
"17 None \n",
"18 None \n",
"19 None 神経膠腫 \n",
"20 None 白血病、悪性リンパ腫、多発性骨髄腫、再生不良性貧血、骨髄異形成症候群 \n",
"21 None \n",
"22 None BRAF融合遺伝子、BRAF遺伝子再構成、低悪性度神経膠腫、膵癌 \n",
"23 None \n",
"24 None \n",
"25 None \n",
"26 None \n",
"27 None \n",
"28 None \n",
"29 None \n",
"30 None \n",
"31 None \n",
"32 None \n",
"33 None \n",
"34 None \n",
"35 None \n",
"36 None \n",
"37 None \n",
"38 None \n",
"39 None \n",
"40 None \n",
"41 None 膠芽腫、退形成性星細胞腫、退形成性乏突起膠腫 \n",
"42 None 脊髄腫瘍 \n",
"43 None \n",
"44 None 悪性神経膠腫 \n",
"\n",
" Keyword \\\n",
"0 \n",
"1 \n",
"2 \n",
"3 \n",
"4 \n",
"5 glioblastoma, grade3/4 astrocytoma, grade3 oli... \n",
"6 \n",
"7 \n",
"8 \n",
"9 \n",
"10 \n",
"11 \n",
"12 \n",
"13 \n",
"14 \n",
"15 \n",
"16 \n",
"17 \n",
"18 \n",
"19 Glioma \n",
"20 Leukemia, malignant lymphoma, multiple myeloma... \n",
"21 \n",
"22 BRAF fusion gene, BRAF rearrangement, low-grad... \n",
"23 \n",
"24 \n",
"25 \n",
"26 \n",
"27 \n",
"28 \n",
"29 \n",
"30 \n",
"31 \n",
"32 \n",
"33 \n",
"34 \n",
"35 \n",
"36 \n",
"37 \n",
"38 \n",
"39 \n",
"40 \n",
"41 gliobalastoma, anaplastic astrocytoma,anaplast... \n",
"42 Spinal cord tumor \n",
"43 \n",
"44 Malignant glioma \n",
"\n",
" 介入の内容 \\\n",
"0 被験者は、ベースラインでONC201週2回投与群、ONC201週1回投与群又はプラセボ投与群... \n",
"1 薬物 アベマシクリブ\\n\\r\\n経口投与\\n\\r\\nその他の名称 LY2835219\\n\\r... \n",
"2 A群：標準治療群[術後化学放射線療法]/ B群：試験治療群[Watch & Wait... \n",
"3 投与群：ABBV-383用量A\\n\\r\\nABBV-383の用量Aを151週間の試験期間中に... \n",
"4 サバトリマブ（MBG453）：静脈内投与\\n\\r\\nアザシチジン：皮下投与又は静脈内投与\\n... \n",
"5 A群：BPC療法\\n\\r\\n悪性神経膠腫に対して保険適用されている化学療法から患者の状態に合... \n",
"6 Teclistamab -\\n\\r\\nTeclistamab，ダラツムマブ皮下投与製剤及びレ... \n",
"7 AZD0305 を3週毎に静脈内投与する\\n \n",
"8 cevostamab：Cevostamabは、1サイクルを28日間として2週間隔、4週間隔に... \n",
"9 エルラナタマブ（投与経路：皮下）\\n\\r\\nエロツズマブ（投与経路：静脈内）\\n\\r\\nポマ... \n",
"10 A群\\n\\r\\n製品：イデカブタゲン ビクルユーセル\\n\\r\\n規定用量を規定された日に投与... \n",
"11 [日本人コホート] \\n\\r\\nMezigdomide/ボルテゾミブ/デキサメタゾン\\n\\r... \n",
"12 A群：Mezigdomide、カルフィルゾミブ、デキサメタゾン\\n\\r\\nB群：カルフィルゾ... \n",
"13 治験治療、自家末梢血幹細胞採取および移植、血液検査、骨髄検査等 \n",
"14 CC-93269 \n",
"15 ＜コホート1＞\\n\\r\\nロムスチン130 mg/m2を6週間ごとに経⼝投与する。\\n\\r\\... \n",
"16 A1群: Iberdomide 用量 1レベル\\n\\r\\nA2群: Iberdomide 用... \n",
"17 パート1:\\n\\r\\n被験薬：Belantamab\\n\\r\\n被験薬：ベランタマブ マホドチ... \n",
"18 被験薬: REGN5458静脈内投与\\n\\r\\n第II相: 疾患進行が認められるまで、又はそ... \n",
"19 本品を使用する患者は、頭髪をすべて剃り、TTF ジェネレーターに接続した４枚のINE トラン... \n",
"20 \n",
"21 薬剤：イサツキシマブ IV（SAR650984）\\n\\r\\n 剤形：バイアル、投与経路：静脈... \n",
"22 ビニメチニブとして1回45 mgを1日2回経口投与する。 \n",
"23 Teclistamab：被験者はteclistamab単剤療法を受ける。Teclistama... \n",
"24 パート1 用量レベル1：エルラナタマブ，ダラツムマブ，レナリドミド\\n\\r\\nパート1 用量... \n",
"25 ・A群（DVRd導入療法 + ASCT + DVRd地固め療法 + レナリドミド維持療法）\\... \n",
"26 1サイクルを28日間とし，ABBV-383（静脈内投与）とポマリドミド（経口）+デキサメタゾ... \n",
"27 Cilta-cel：本試験は、先行試験でcilta-celの投与を受けた被験者に対する追跡調... \n",
"28 Elranatamab \\n\\r\\nBCMAおよびCD3を標的とする二重特異性抗体\\n\\r\\... \n",
"29 標準治療後の再発悪性神経膠腫の患者を対象に、サイクロトロン中性子照射システム（NeuCure... \n",
"30 ide-celの添付文書、治験実施医療機関の通常診療慣行に従い、また担当医師の判断に基づき、... \n",
"31 ダラツムマブ\\n\\r\\nA群:Teclistamab-ダラツムマブ（Tec-Dara）\\n\\... \n",
"32 被験薬：Belantamab mafodotin（ヒト化抗BCMAモノクローナル抗体）\\n\\... \n",
"33 \n",
"34 1. ダラツムマブ+レナリドミド+デキサメサゾン併用寛解導入療法 (DRD療法)\\n\\r\\n... \n",
"35 1)寛解導入療法\\n\\r\\nDRD療法 1,2コース:Dara IV 16mg/kg or ... \n",
"36 DSP-0390を1日1回経口投与する。1サイクルを28日間とし、安全性及び治療レスポンスを... \n",
"37 A群\\n\\r\\n被験者は，ランダム化を行う前にボルテゾミブ，レナリドミド及びデキサメタゾン(... \n",
"38 【IberDd】第1ステージにおいて、Iberdomide（CC-220）1.0mg、1.3... \n",
"39 導入療法（A・B群共通）：D-MPB療法（3週1コースとして合計18コース行う）、第1コース... \n",
"40 OPC-415 (上限1×10^7個/kg), 2日間投与\\n \n",
"41 プロトコル治療は放射線照射療法の適用が決定次第、開始される。プロトコル治療の併用療法として、... \n",
"42 ACNU（0.25 mg/ml, 4ml）のCED法による脊髄髄内注入\\n\\r\\nテモゾロミ... \n",
"43 1）WT1-W10ペプチド癌ワクチン療法\\n\\r\\nWT1-W10ペプチド癌ワクチン療法とし... \n",
"44 VEGFR1およびVEGFR2ペプチド(各2mg)とIFA混合液の皮下投与。毎週投与８回後、... \n",
"\n",
" Intervention(s) 試験の種類 Study Type \n",
"0 Participants will be randomized at baseline in... NaN NaN \n",
"1 Drug: Abemaciclib\\n\\r\\nAdministered orally\\n\\r... NaN NaN \n",
"2 Group A: Standard treatment group [Adjuvant ch... 介入研究 Interventional \n",
"3 Experimental: ABBV-383 Dose A\\n\\r\\nParticipant... NaN NaN \n",
"4 Sabatolimab (MBG453): Solution for intravenous... NaN NaN \n",
"5 Group A: BPC Therapy\\n\\r\\nDepending on the pat... NaN NaN \n",
"6 Teclistamab-Teclistamab, Daratumumab SC, Lenal... NaN NaN \n",
"7 AZD0305 IV every 3 weeks\\n NaN NaN \n",
"8 cevostamab: Cevostamab will be administered in... NaN NaN \n",
"9 Drug: Elranatamab\\n\\r\\nElranatamab will be adm... NaN NaN \n",
"10 ArmA\\n\\r\\nBiological: idecabtagene vicleucel\\n... NaN NaN \n",
"11 [Japan safety lead-in cohort]\\n\\r\\nMezigdomide... NaN NaN \n",
"12 Arm A: Mezigdomide, Carfilzomib and Dexamethas... NaN NaN \n",
"13 Study treatment,Autologous Peripheral Blood St... NaN NaN \n",
"14 CC-93269 NaN NaN \n",
"15 <cohort1>\\n\\r\\nLomustine 130 mg/m2 orall... NaN NaN \n",
"16 Arm A1: Iberdomide Dose 1\\n\\r\\nArm A2: Iberdom... NaN NaN \n",
"17 Part1:\\n\\r\\nDrug: Belantamab\\n\\r\\nDrug: Belant... NaN NaN \n",
"18 Drug: REGN5458 administered by intravenous (IV... NaN NaN \n",
"19 The patient using the product should shave all... NaN NaN \n",
"20 観察研究 Observational \n",
"21 Drug: Isatuximab IV (SAR650984)\\n\\r\\n Pharmace... NaN NaN \n",
"22 Binimetinib is administered 45 mg orally, twic... NaN NaN \n",
"23 Teclistamab: Participants will receive teclist... NaN NaN \n",
"24 Part 1 Dose Level 1:Elranatamab, Daratumumab, ... NaN NaN \n",
"25 - Arm A (DVRd Induction + ASCT + DVRd Consolid... NaN NaN \n",
"26 Participants will receive intravenous (IV) ABB... NaN NaN \n",
"27 Cilta-cel:Participants who had received cilta-... NaN NaN \n",
"28 Drug: Elranatamab \\n\\r\\nBCMA-CD3 bispecific an... NaN NaN \n",
"29 BNCT is performed in combination with a cyclot... 介入研究 Interventional \n",
"30 In accordance with the ide-cel prescribing inf... NaN NaN \n",
"31 Daratumumab\\n\\r\\nArm A: Teclistamab-daratumuma... NaN NaN \n",
"32 Belantamab mafodotin (anti-BCMA (B-cell matura... NaN NaN \n",
"33 NaN NaN \n",
"34 1. Daratumumab + lenalidomide + dexamethasone ... 介入研究 Interventional \n",
"35 1) Induction therapy\\n\\r\\nDRD therapy 1,2 cour... 介入研究 Interventional \n",
"36 Patients will receive DSP-0390 orally once dai... NaN NaN \n",
"37 Arm A\\n\\r\\nParticipants will receive bortezomi... NaN NaN \n",
"38 [IberDd] At the First Stage, Iberdomide (CC-22... NaN NaN \n",
"39 Induction therapy (both arm A and arm B) D-MPB... 介入研究 Interventional \n",
"40 OPC-415 (up to 1X10^7cells/kg)\\n\\r\\nOn 2 days\\... NaN NaN \n",
"41 1)Arm A: Patients randomly selected group have... 介入研究 Interventional \n",
"42 ACNU delivery (0.25 mg/ml, 4ml) into the spin... 介入研究 Interventional \n",
"43 1)\\tWT1-W10 peptide immunotherapy\\n\\r\\nIntrade... 介入研究 Interventional \n",
"44 Subcutaneous injection of VEGFR1 and VEGFR2 pe... 介入研究 Interventional \n",
"\n",
"[45 rows x 32 columns]"
]
},
"execution_count": 29,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"sorted_df"
]
},
{
"cell_type": "code",
"execution_count": null,
"metadata": {},
"outputs": [],
"source": []
}
],
"metadata": {
"kernelspec": {
"display_name": "gradio",
"language": "python",
"name": "python3"
},
"language_info": {
"codemirror_mode": {
"name": "ipython",
"version": 3
},
"file_extension": ".py",
"mimetype": "text/x-python",
"name": "python",
"nbconvert_exporter": "python",
"pygments_lexer": "ipython3",
"version": "3.12.3"
}
},
"nbformat": 4,
"nbformat_minor": 2
}
|